What is Noble Financial’s Estimate for UNCY Q1 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at Noble Financial issued their Q1 2027 earnings estimates for Unicycive Therapeutics in a report released on Wednesday, July 1st. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of $0.85 for the quarter. Noble Financial currently has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.18 EPS and Q4 2027 earnings at $1.38 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

A number of other analysts also recently commented on UNCY. Weiss Ratings upgraded Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. B. Riley Financial reiterated a “buy” rating and issued a $22.00 target price on shares of Unicycive Therapeutics in a report on Tuesday. Benchmark lowered their price target on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday. HC Wainwright lowered their price target on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Guggenheim restated a “buy” rating and issued a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Unicycive Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $27.40.

Unicycive Therapeutics Stock Up 12.6%

Shares of UNCY opened at $5.28 on Thursday. The firm has a market cap of $144.62 million, a PE ratio of -2.39 and a beta of 1.80. The company’s fifty day moving average is $7.46 and its two-hundred day moving average is $6.82. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $8.74.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently bought and sold shares of UNCY. Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics in the second quarter worth $55,000. JPMorgan Chase & Co. lifted its holdings in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Unicycive Therapeutics during the 1st quarter valued at $161,000. Citadel Advisors LLC purchased a new stake in Unicycive Therapeutics during the 3rd quarter worth $182,000. Finally, Bank of America Corp DE boosted its position in Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after purchasing an additional 29,378 shares during the period. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial and Brookline Capital Markets reiterated a constructive long-term view, with Noble assigning an Outperform rating and $50 target while modeling strong 2027 earnings and Brookline raising its FY2030 EPS estimate. Analyst target update
• Positive Sentiment: Despite the FDA setback, the company said the agency did not raise concerns about OLC’s clinical efficacy or safety data and requested no additional clinical data, which leaves the door open for a future resubmission. FDA CRL summary
• Neutral Sentiment: Unicycive said it is in ongoing discussions with the FDA over labeling and packaging and remains optimistic about resolving the manufacturing issues, but there is still no clear timeline for approval. Investigation notice
• Negative Sentiment: Multiple law firms launched securities-fraud investigations into Unicycive after the FDA rejection, adding legal and reputational overhang for shareholders. Investor alert
• Negative Sentiment: Benchmark, Noble Financial, and HC Wainwright all lowered price targets, reflecting reduced near-term confidence after the regulatory setback. Price target cuts

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.